Capital Management Ii, Llc ... Net Worth

The estimated Net Worth of Capital Management Ii, Llc ... is at least $56.8 million dollars as of 6 October 2016. Capital Llc owns over 50,000 units of Aimmune Therapeutics Inc stock worth over $47,504,595 and over the last 9 years Capital sold AIMT stock worth over $9,327,400.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Capital Llc AIMT stock SEC Form 4 insiders trading

Capital has made over 7 trades of the Aimmune Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Capital sold 50,000 units of AIMT stock worth $2,017,000 on 6 October 2016.

The largest trade Capital's ever made was buying 642,035 units of Aimmune Therapeutics Inc stock on 11 August 2015 worth over $10,349,604. On average, Capital trades about 242,503 units every 60 days since 2015. As of 6 October 2016 Capital still owns at least 1,672,697 units of Aimmune Therapeutics Inc stock.

You can see the complete history of Capital Llc stock trades at the bottom of the page.

Insiders trading at Aimmune Therapeutics Inc

Over the last 9 years, insiders at Aimmune Therapeutics Inc have traded over $19,285,948 worth of Aimmune Therapeutics Inc stock and bought 61,698,079 units worth $2,225,231,200 . The most active insiders traders include Des Produits Nestle S.A. So..., Patrick G Enright et Des Produits Nestle S.A.Nes.... On average, Aimmune Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $21,038,606. The most recent stock trade was executed by Des Produits Nestle S.A. So... on 13 October 2020, trading 54,117,287 units of AIMT stock currently worth $1,867,046,402.

What does Aimmune Therapeutics Inc do?

Complete history of Capital Llc stock trades at Aerie Pharmaceuticals Inc et Aimmune Therapeutics Inc

Aimmune Therapeutics Inc executives and stock owners

Aimmune Therapeutics Inc executives and other stock owners filed with the SEC include:

• Stacey Denenberg Seltzer,
  Director
• Jeffrey H Knapp,
  Chief Operating Officer
• Susan E. Barrowcliffe,
  General Manager, Europe
• Capital Partners Ii, Llc Ta...,
  
• Kathryn E Falberg,
  Director
• Daniel C Md Adelman,
  Chief Medical Officer
• Mary M. Rozenman,
  See Remarks
• Capital Management Ii, Llc ...,
  
• Capital Partners Ii, Llc Lo...,
  
• Gregory Behar,
  Director
• Douglas T. Sheehy,
  See Remarks
• Mark T Iwicki,
  Director
• Eric Bjerkholt,
  Chief Financial Officer
• Mark Mcdade,
  Director
• Warren L. De Souza,
  Chief Financial Officer
• Robert Myles Elfont,
  Chief Medical Officer
• Jayson Donald Alexander Dallas,
  President and CEO
• Health Science Us Holdings,...,
  
• Des Produits Nestle S.A.Nes...,
  
• Bakker Juliet Tammenoms,
  10% owner
• Stephen George Dilly,
  See Remarks
• Andrew Oxtoby,
  Chief Commercial Officer
• Capital Partners Ii, Llc Ta...,
  
• Patrick G Enright,
  Director
• Brett K Haumann,
  Director
• Des Produits Nestle S.A. So...,
  10% owner